ZHONGHENG GROUP(SH:600252) Ge Long Hui A P P·2025-08-04 11:13Core Viewpoint - Zhongheng Group (600252.SH) is acquiring a patented technology for treating chronic heart failure from the Navy Medical University of the People's Liberation Army, aligning with its strategic development goals [1] Summary by Relevant Sections Acquisition Details - Zhongheng Innovation, a wholly-owned subsidiary of Zhongheng Group, plans to acquire the patent for a drug technology aimed at treating chronic heart failure [1] - The project has a base transfer price of RMB 55 million, with a deposit of RMB 500,000 required [1] - The transfer process includes an initial payment of at least RMB 5 million, due within 10 working days after the contract takes effect, followed by milestone payments upon the occurrence of specified events [1] Timeline and Confirmation - The transfer listing will end on June 18, 2025, with the confirmation of Zhongheng Innovation as the acquirer occurring on June 20, 2025 [1] - A formal contract for the technology transfer was signed between Zhongheng Innovation and the China Runtong Research Institute on August 1, 2025 [1]